孟鲁司特钠辅助布地奈德雾化吸入治疗儿童哮喘疗效观察  

Effect of montelukast sodium combined with budesonide for aerosol inhalation in the treatment of children with asthma and its influence on lung function and inflammation index

作　　者：曹军[1] 曹雅婷 王泽仲 CAO Jun;CAO Ya-ting;WANG Ze-zhong(Department of Pediatrics,Dongguan Chang'an Hospital,Dongguan 523840,Guangdong,CHINA;Department of Pediatrics,Shenzhen Maternal and Child Health Hospital,Shenzhen 518048,Guangdong,CHINA;Department of Pediatrics,Jingzhou No.1 Hospital,Jingzhou 434000,Hubei,CHINA)

机构地区：[1]东莞市长安医院儿科,广东东莞523840 [2]深圳市妇幼保健院儿科,广东深圳518048 [3]荆州市第一医院儿科,湖北荆州434000

出　　处：《海南医学》2020年第11期1412-1415,共4页Hainan Medical Journal

摘　　要：目的探讨孟鲁司特钠辅助布地奈德雾化吸入治疗儿童哮喘的疗效及对患儿肺功能和炎症因子的影响。方法选择东莞市长安医院2017年3月至2019年9月收治的60例哮喘患儿进行研究,按照随机数表法将患儿均分为对照组和观察组,每组30例。对照组采取布地奈德雾化吸入治疗,观察组采取孟鲁司特钠辅助布地奈德雾化吸入治疗。20 d为一个疗程,治疗3个疗程后比较两组患儿的临床疗效、治疗前后的呼气流量峰值(PEF)、第1秒用力呼气量(FEV1)、用力肺活量(FVC)指标及白细胞介素-6 (IL-6)、肿瘤坏死因子-α(TNF-α)、血清超能C反应蛋白(hs-CRP)指标,并统计两组患儿的不良反应情况。结果观察组患儿的治疗总有效率为96.66%,明显高于对照组的73.33%,差异有统计学意义(P<0.05);治疗前,两组患儿的PEF、FEV1、FVC水平比较差异均无统计学意义(P>0.05);治疗后,观察组患儿的PEF、FEV1、FVC水平分别为(3.85±0.71) L/s、(3.54±0.54) L、(3.97±0.41) L,明显高于对照组的(2.94±0.86) L/s、(2.84±0.30) L、(3.42±0.40) L,差异均有统计学意义(P<0.05);治疗前,两组患儿的IL-6、TNF-α、hs-CRP水平比较差异均无统计学意义(P>0.05);治疗后,观察组患儿的IL-6、TNF-α、hs-CRP水平分别为(43.16±12.42) pg/m L、(0.52±0.09) pg/m L、(8.01±1.28) mg/L,明显低于对照组的(100.88±18.64) pg/m L、(0.72±0.10) pg/m L、(11.78±2.23) mg/L,差异均有统计学意义(P<0.05);观察组患儿的总不良反应发生率为3.33%,明显低于对照组的20.00%,差异有统计学意义(P<0.05)。结论孟鲁司特钠辅助布地奈德雾化吸入治疗儿童哮喘能够有效改善患儿肺功能、炎症水平,降低不良反应的发生率,临床治疗效果显著。Objective To investigate the effect of montelukast sodium combined with budesonide for aerosol inhalation in the treatment of childhood asthma and its effect on pulmonary function and inflammatory factors.Methods Sixty children with asthma who received treatment in Dongguan Chang'an Hospital from March 2017 to September 2019 were selected for study.According to the random number table,the children were divided into control group and observation group,with 30 children in each group.The control group was treated with budesonide,and the observation group was treated with montelukast sodium combined with budesonide for aerosol inhalation.After three courses of treatment,the clinical efficacy,peak expiratory flow(PEF),forced expiratory volume in the first second(FEV1),forced vital capacity(FVC),interleukin-6(IL-6),and tumor necrosis factor alpha(TNF-α)were analyzed before and after treatment.TNF-αand serum high-sensitivity C-reactive protein(hs-CRP)were measured,and the adverse reactions of the two groups were analyzed.Results The total effective rate of the observation group was 96.66%,significantly higher than 73.33%of the control group(P<0.05).Before treatment,there was no significant difference in PEF,FEV1,and FVC between the two groups(P>0.05);after treatment,the PEF,FEV1,and FVC levels in the observation group were(3.85±0.71)L/s,(3.54±0.54)L,(3.97±0.41)L,which were significantly higher than(2.94±0.86)L/s,(2.84±0.30)L,(3.42±0.40)L in the control group(P<0.05).Before treatment,there was no significant difference in the levels of IL-6,TNF-α,and hs-CRP between the two groups(P>0.05);after treatment,the levels of IL-6,TNF-αand hs CRP in the observation group were(43.16±12.42)pg/mL,(0.52±0.09)pg/mL,(8.01±1.28)mg/L,which were significantly lower than(100.88±18.64)pg/mL,(0.72±0.10)pg/mL,(11.78±2.23)mg/L in the control group(P<0.05).The total incidence of adverse reactions in the observation group was 3.33%,which was significantly lower than 20.00%in the control group(P<0.05).Conclusion Montelukast sodium

关 键 词：哮喘 孟鲁司特钠 布地奈德 肺功能 炎症因子 疗效 不良反应 

分 类 号：R725.6[医药卫生—儿科]